Literature DB >> 20727896

A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.

M Chen1, J S Chang, M Nason, D Rangel, J G Gall, B S Graham, J E Ledgerwood.   

Abstract

Respiratory syncytial virus (RSV) is an important cause of respiratory infection in people of all ages, and is the leading cause of hospitalization in infants. Although commercially available monoclonal antibody is available for passive prophylaxis of neonates at risk of severe disease, there is no available vaccine to prevent RSV. Measurement of neutralizing activity will be a key endpoint for vaccine evaluation. Assessment of neutralizing antibody against RSV has been limited to traditional plaque reduction, which is time-consuming and inherently operator dependent and highly variable. Here, we describe a flow cytometry-based RSV-specific neutralization assay which is more rapid than traditional methods, highly sensitive and highly reproducible. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727896      PMCID: PMC2964415          DOI: 10.1016/j.jim.2010.08.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

Review 1.  Mechanisms of virus neutralization by antibody.

Authors:  P J Klasse; Q J Sattentau
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Authors:  Theodore C Pierson; Melissa D Sánchez; Bridget A Puffer; Asim A Ahmed; Brian J Geiss; Laura E Valentine; Louis A Altamura; Michael S Diamond; Robert W Doms
Journal:  Virology       Date:  2005-12-02       Impact factor: 3.616

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay.

Authors:  L J Anderson; J C Hierholzer; P G Bingham; Y O Stone
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

8.  A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.

Authors:  Julie E Martin; Theodore C Pierson; Sarah Hubka; Steve Rucker; Ingelise J Gordon; Mary E Enama; Charla A Andrews; Qing Xu; Brent S Davis; Martha Nason; Michael Fay; Richard A Koup; Mario Roederer; Robert T Bailer; Phillip L Gomez; John R Mascola; Gwong-Jen J Chang; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

9.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Authors:  Junji Sashihara; Peter D Burbelo; Barbara Savoldo; Theodore C Pierson; Jeffrey I Cohen
Journal:  Virology       Date:  2009-07-07       Impact factor: 3.616

10.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

View more
  21 in total

1.  Immunogenicity of novel mumps vaccine candidates generated by genetic modification.

Authors:  Pei Xu; Zhenhai Chen; Shannon Phan; Adrian Pickar; Biao He
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Authors:  Min Zhao; Zi-Zheng Zheng; Man Chen; Kayvon Modjarrad; Wei Zhang; Lu-Ting Zhan; Jian-Li Cao; Yong-Peng Sun; Jason S McLellan; Barney S Graham; Ning-Shao Xia
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

3.  Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection.

Authors:  Sandra Fuentes; Roberta L Crim; Judy Beeler; Michael N Teng; Hana Golding; Surender Khurana
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

4.  Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.

Authors:  Jason S McLellan; Man Chen; Jung-San Chang; Yongping Yang; Albert Kim; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

5.  Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

Authors:  Jason S McLellan; Bruno E Correia; Man Chen; Yongping Yang; Barney S Graham; William R Schief; Peter D Kwong
Journal:  J Mol Biol       Date:  2011-04-27       Impact factor: 5.469

6.  Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.

Authors:  Corey Balinsky; Vihasi Jani; Peifang Sun; Maya Williams; Gabriel Defang; Kevin R Porter
Journal:  Methods Mol Biol       Date:  2022

7.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

8.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

9.  An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting.

Authors:  Yvonne van Remmerden; Fang Xu; Mandy van Eldik; Jacco G M Heldens; Willem Huisman; Myra N Widjojoatmodjo
Journal:  Virol J       Date:  2012-10-31       Impact factor: 4.099

10.  A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment.

Authors:  Jan C Varada; Belete Teferedegne; R Lynne Crim; Thembi Mdluli; Susette Audet; Keith Peden; Judy Beeler; Haruhiko Murata
Journal:  Virol J       Date:  2013-06-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.